Interpretation of Clinical Practice Guidelines for Management of Kidney Injury during Anticancer Drug Therapy 2022 (Ⅶ): management of anticancer drug-induced kidney injury
10.3760/cma.j.cn114015-20240831-00027
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（七）：抗肿瘤药物相关肾损伤的管理
- Author:
Yan SONG
1
;
Lingyi XU
;
Simiao ZHAO
;
Xizi ZHENG
;
Li YANG
Author Information
1. 解放军总医院第一医学中心肾脏病学部肾脏病科，北京 100853
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Acute kidney injury;
Kidney diseases;
Guideline
- From:
Adverse Drug Reactions Journal
2024;26(11):641-646
- CountryChina
- Language:Chinese
-
Abstract:
Anticancer drugs are important causes of kidney injury in cancer patients. Once kidney injury occurs, it will affect anticancer therapy and patient prognosis. Thus, the Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 and made a particular discussion on the prevention and management of anticancer drug-induced kidney injury. This article focuses on interpreting the management of kidney injury related to cytotoxic anticancer drugs, targeted therapies, and immune checkpoint inhibitors to more effectively guide clinical practice.
